1. Home
  2. NEOG vs MLYS Comparison

NEOG vs MLYS Comparison

Compare NEOG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neogen Corporation

NEOG

Neogen Corporation

HOLD

Current Price

$9.60

Market Cap

1.9B

Sector

Health Care

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$27.18

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NEOG
MLYS
Founded
1981
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
2.2B
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
NEOG
MLYS
Price
$9.60
$27.18
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$10.67
$48.67
AVG Volume (30 Days)
2.5M
1.2M
Earning Date
04-09-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.43
EPS
0.02
N/A
Revenue
$894,661,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.67
N/A
P/E Ratio
$458.25
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.32
$12.59
52 Week High
$11.43
$47.65

Technical Indicators

Market Signals
Indicator
NEOG
MLYS
Relative Strength Index (RSI) 50.53 53.22
Support Level $8.93 $26.85
Resistance Level $10.30 $31.09
Average True Range (ATR) 0.52 1.65
MACD 0.07 0.38
Stochastic Oscillator 44.32 62.11

Price Performance

Historical Comparison
NEOG
MLYS

About NEOG Neogen Corporation

Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety. In food safety, the company performs diagnostics to detect unintended substances in food and animal feed, to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. In animal safety, the company segment is engaged in the development, manufacture, marketing and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Share on Social Networks: